His meeting with a specialist was an eye-opener. That’s when his doctor said, “I’m pretty sure you’ve got cornea dystrophy. I’m going to have to replace your cornea." It was something ...

Identifying the mutations which cause ocular surface disorders and in doing so they facilitate improved diagnosis and treatment in the ageing or diseased eye. The Genomic Medicine Research Group at ...

The fuchs endothelial corneal dystrophy market is expected to experience significant growth in the coming years, propelled by the development of innovative non-surgical therapies, an increasing ...

Design Therapeutics, Inc., a biotechnology company focused on treatments for genetic diseases, announced it will provide an update on its DT-168 program for Fuchs endothelial corneal dystrophy ...

today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025 ...

DT-168 is a GeneTAC® small molecule, formulated as an eye drop, that is designed to selectively target the CTG repeat expansion in the TCF4 gene and reduce the expression of the mutant gene product ...